Cocrystal Pharma Q4 2021 Earnings Report
Key Takeaways
Cocrystal Pharma reported no revenues for 2021 compared to $2.0 million in 2020 due to Merck assuming activities and expenses for the influenza A/B collaboration. R&D expenses increased to $8.8 million, and the net loss was $14.2 million, or $0.16 per share. The company's cash position remains strong with $58.7 million.
Enrollment is underway in Phase 1 trial with antiviral compound CC-42344 for influenza A.
Plans to initiate first-in-human clinical studies in 2022 with two SARS-CoV-2 protease inhibitors.
Received extensive comments from the FDA on pre-IND briefing package for CDI-45205.
Company is well positioned to execute on its strategy with a clean capital structure and sufficient cash balance through 2023.
Cocrystal Pharma
Cocrystal Pharma
Forward Guidance
The Company expects R&D expenses to increase during 2022 due to the advancement of our influenza A program into the clinic and progress with preclinical COVID-19 programs toward clinical development.